[go: up one dir, main page]

MX2009002944A - Analogos de 2-metilen-(20s,25s)-19,27-dinor-(22e)-vitamina d. - Google Patents

Analogos de 2-metilen-(20s,25s)-19,27-dinor-(22e)-vitamina d.

Info

Publication number
MX2009002944A
MX2009002944A MX2009002944A MX2009002944A MX2009002944A MX 2009002944 A MX2009002944 A MX 2009002944A MX 2009002944 A MX2009002944 A MX 2009002944A MX 2009002944 A MX2009002944 A MX 2009002944A MX 2009002944 A MX2009002944 A MX 2009002944A
Authority
MX
Mexico
Prior art keywords
dinor
methylene
skin
compound
analogs
Prior art date
Application number
MX2009002944A
Other languages
English (en)
Inventor
Lori A Plum
Margaret Clagett-Dame
Hector Deluca
Grazia Chiellini
Pawel Grzywacz
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of MX2009002944A publication Critical patent/MX2009002944A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Está invención describe análogos de 2-metilen-(20S,25S)-2-metilen- (22E)-vitamina D, y específicamente 2-metilen-(20S,25S)-19,27-dino r-(22E)-1?,25-dihidroxi vitamina D3, y sus usos farmacéuticos. Este compuesto exhibe actividad pronunciada para frenar la proliferación de células no diferenciadas e inducir su diferenciación al monocito, de esta manera evidenciando el uso como un agente anticáncer y para el tratamiento de enfermedades de la piel tales como psoriasis así como condiciones de la piel tales como arrugas, piel holgada, piel seca e insuficiente secreción de sebo. Este compuesto también tiene poca, de haber, actividad calcémica y por lo tanto puede utilizarse para tratar desórdenes autoinmunes o enfermedades inflamatorias en humanos así como osteodistrofia renal. Este compuesto también puede empelarse para el tratamiento o prevención de obesidad.
MX2009002944A 2006-09-28 2007-09-25 Analogos de 2-metilen-(20s,25s)-19,27-dinor-(22e)-vitamina d. MX2009002944A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84880506P 2006-09-28 2006-09-28
PCT/US2007/079381 WO2008039751A2 (en) 2006-09-28 2007-09-25 2-methylene-(20s,25s)-19,27-dinor-(22e)-vitamin d analogs

Publications (1)

Publication Number Publication Date
MX2009002944A true MX2009002944A (es) 2009-04-02

Family

ID=39172159

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009002944A MX2009002944A (es) 2006-09-28 2007-09-25 Analogos de 2-metilen-(20s,25s)-19,27-dinor-(22e)-vitamina d.

Country Status (9)

Country Link
US (1) US8114859B2 (es)
EP (1) EP2069296B1 (es)
JP (1) JP2010504994A (es)
AT (1) ATE552238T1 (es)
AU (1) AU2007300211A1 (es)
CA (1) CA2662864A1 (es)
MX (1) MX2009002944A (es)
NZ (1) NZ575159A (es)
WO (1) WO2008039751A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399439B2 (en) 2008-07-10 2013-03-19 Wisconsin Alumni Research Foundation 2-methylene-19,26-dinor-(20S,22E,25R)-vitamin D analogs
AU2010300528B2 (en) * 2009-10-02 2016-02-11 Wisconsin Alumni Research Foundation (20S,22E)-2-methylene-19-nor-22-ene-1alpha,25-dihydroxyvitamin D3 analogs
CA2824870C (en) * 2011-06-14 2018-08-14 Wisconsin Alumni Research Foundation 3-desoxy-2-methylene-19-nor-vitamin d analogs and their uses
US9545302B2 (en) 2013-11-20 2017-01-17 Dermagenesis Llc Skin printing and auto-grafting
US20150140058A1 (en) * 2013-11-20 2015-05-21 Dermagenesis Llc Skin printing and auto-grafting

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486333A (en) * 1981-04-10 1984-12-04 Felix Sebba Preparation of biliquid foam compositions
US4666634A (en) 1984-12-05 1987-05-19 Chugai Seiyaku Kabushiki Kaisha vitamin D3 derivatives having a substituent at 2-position
US5086191A (en) 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
DE69400495T2 (de) 1993-04-05 1997-04-30 Wisconsin Alumni Res Found 19-Nor-vitamin-D3-Verbindung mit einem Substituent an die 2. Stelle
US5843928A (en) 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US5945410A (en) 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
BR122012030847B1 (pt) * 1999-04-23 2021-07-06 Leo Pharma A/S Composição farmacêutica não aquosa para uso dermatológico, e, uso da mesma
PT1286962E (pt) 2000-05-31 2008-07-30 Wisconsin Alumni Res Found Compostos de 2-etil- e 2-etilideno-19-nor-vitamina d
WO2002009427A1 (en) 2000-07-21 2002-01-31 Koninklijke Philips Electronics N.V. Method and system for determining a user profile
AU2001275445B2 (en) 2000-09-08 2006-07-27 Wisconsin Alumni Research Foundation 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications
US6627622B2 (en) 2002-02-18 2003-09-30 Wisconsin Alumni Research Foundation (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
US6566352B1 (en) 2002-02-18 2003-05-20 Wisconsin Alumni Research Foudation 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
US20050009792A1 (en) 2003-07-08 2005-01-13 Deluca Hector F. (20S)-1alpha-hydroxy-2-methylene-19-nor-vitamin D3 and its uses
CA2544502A1 (en) * 2003-11-25 2005-06-09 Wisconsin Alumni Research Foundation Vitamin d analogs for obesity prevention and treatment
WO2006057884A2 (en) 2004-11-22 2006-06-01 Wisconsin Alumni Research Foundation 2α-METHYL AND 2ß-METHYL ANALOGS OF 19,26,27-TRINOR-(20S)-1α-HYDROXYVITAMIN D3 AND THEIR USES
US7528122B2 (en) * 2006-02-02 2009-05-05 Wisconsin Alumni Research Foundation Vitamin D analog—NEL, methods and uses thereof
WO2008035207A2 (en) 2006-04-06 2008-03-27 Wisconsin Alumni Research Foundation 2-methylene-1alpha-hydroxy-19,21-dinorvitamin d3 analogs and uses thereof

Also Published As

Publication number Publication date
EP2069296B1 (en) 2012-04-04
WO2008039751A2 (en) 2008-04-03
EP2069296A2 (en) 2009-06-17
JP2010504994A (ja) 2010-02-18
CA2662864A1 (en) 2008-04-03
ATE552238T1 (de) 2012-04-15
WO2008039751A3 (en) 2008-05-22
NZ575159A (en) 2012-04-27
US8114859B2 (en) 2012-02-14
US20080081799A1 (en) 2008-04-03
AU2007300211A1 (en) 2008-04-03

Similar Documents

Publication Publication Date Title
MX2007006263A (es) Analogos 2a-metil y 2??-metil de 19,26,27-trinor-(20s)-1a- hidroxivitamina d3 y sus usos.
EP1482951B8 (en) 1-alpha-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
IL154699A0 (en) 1alpha-HYDROXY-2-METHYLENE-19-NOR-HOMOPREGNACALCIFEROL AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
MX2010007205A (es) Analogos de vitamina d, 2-metilen-20-metil-19, 24, 25, 26, 27-pentanor.
MX2009003241A (es) Analogos de 2-metilen-(20r,25s)-19,27-dinor-(22e)-vitamina d.
WO2006057899A3 (en) 2alpha-methyl-19-nor-(20s)-1alpha-hydroxy-bishomopregnacalciferol and its uses
WO2006057886A8 (en) 2-METHYLENE-19,26,27-TRINOR-(20S)-1α-HYDROXYVITAMIN D3 AND ITS USES
WO2006057885A3 (en) 17,20(e)-dehydro vitamin d analogs and their uses
MX2010007264A (es) Análogos de vitamina d 2-metilen-(20s, 25r)-19, 26-dinor.
MX2009002944A (es) Analogos de 2-metilen-(20s,25s)-19,27-dinor-(22e)-vitamina d.
SI1453798T1 (sl) (20S)-1alfa -hidroksi-2-metilen-19-nor-bishomopregnakalciferol in njegove uporabe
WO2010006169A3 (en) 2-methylene-19, 26-dinor-(20s, 22e, 25r)-vitamin d analogs
WO2010006125A3 (en) 2-methylene-19,26-dinor-(20r,22e,25r)-vitamin d analogs
WO2006057932A3 (en) 2-METHYLENE-18,19-DINOR-1α-HYDROXY-HOMOPREGNACALCIFEROL AND ITS USES
WO2009086439A3 (en) 2-methylene-(20s,25s)-19,26-dinor-vitamin d analogs
WO2010006172A3 (en) 2-methylene-20(21)-dehydro-19-nor-vitamin d analogs
WO2006057902A3 (en) 2alpha-methyl-19-nor-1alpha-hydroxy-homopregnacalciferol and its uses
WO2010006135A3 (en) 2-methylene-(17z)-17(20)-dehydro-19,21-dinor-vitamin d analogs
ATE496885T1 (de) 1-alpha-hydroxy-2-(3'-hydroxypropyliden)-19-nor vitamin-d-verbindungen mit einer 1,1- dimethylpropyl-seitenkette
WO2010006129A3 (en) 2-methylene-(22e)-25-(1-methylene-hexyl)-26,27-cyclo-22-dehydro-19-nor-vitamin d analogs

Legal Events

Date Code Title Description
FA Abandonment or withdrawal